http://purl.org/np/RA5I80bakV6K-AUQuFwaNohFxsuBpuCJR8g_e1vzs3vgs#Head
http://purl.org/np/RA5I80bakV6K-AUQuFwaNohFxsuBpuCJR8g_e1vzs3vgs
http://www.nanopub.org/nschema#hasAssertion
http://purl.org/np/RA5I80bakV6K-AUQuFwaNohFxsuBpuCJR8g_e1vzs3vgs#assertion
http://purl.org/np/RA5I80bakV6K-AUQuFwaNohFxsuBpuCJR8g_e1vzs3vgs
http://www.nanopub.org/nschema#hasProvenance
http://purl.org/np/RA5I80bakV6K-AUQuFwaNohFxsuBpuCJR8g_e1vzs3vgs#provenance
http://purl.org/np/RA5I80bakV6K-AUQuFwaNohFxsuBpuCJR8g_e1vzs3vgs
http://www.nanopub.org/nschema#hasPublicationInfo
http://purl.org/np/RA5I80bakV6K-AUQuFwaNohFxsuBpuCJR8g_e1vzs3vgs#pubinfo
http://purl.org/np/RA5I80bakV6K-AUQuFwaNohFxsuBpuCJR8g_e1vzs3vgs
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.nanopub.org/nschema#Nanopublication
http://purl.org/np/RA5I80bakV6K-AUQuFwaNohFxsuBpuCJR8g_e1vzs3vgs#assertion
http://purl.obolibrary.org/obo/DOID_1040
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Disease
http://purl.org/np/RA5I80bakV6K-AUQuFwaNohFxsuBpuCJR8g_e1vzs3vgs#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#object
http://purl.obolibrary.org/obo/DOID_1040
http://purl.org/np/RA5I80bakV6K-AUQuFwaNohFxsuBpuCJR8g_e1vzs3vgs#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate
https://w3id.org/biolink/vocab/treats
http://purl.org/np/RA5I80bakV6K-AUQuFwaNohFxsuBpuCJR8g_e1vzs3vgs#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
https://identifiers.org/drugbank:DB06769
http://purl.org/np/RA5I80bakV6K-AUQuFwaNohFxsuBpuCJR8g_e1vzs3vgs#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement
http://purl.org/np/RA5I80bakV6K-AUQuFwaNohFxsuBpuCJR8g_e1vzs3vgs#association
http://www.w3.org/2000/01/rdf-schema#label
bendamustine hydrochloride injection is an alkylating drug indicated for treatment of patients with chronic lymphocytic leukemia cll efficacy relative to first line therapies other than chlorambucil has not been established 1 1 indolent b cell non hodgkin lymphoma nhl that has progressed during or within six months of treatment with rituximab or a rituximab containing regimen 1 2 bendamustine hydrochloride injection is indicated for the treatment of patients with chronic lymphocytic leukemia efficacy relative to first line therapies other than chlorambucil has not been established bendamustine hydrochloride injection is indicated for the treatment of patients with indolent b cell non hodgkin lymphoma that has progressed during or within six months of treatment with rituximab or a rituximab containing regimen
http://purl.org/np/RA5I80bakV6K-AUQuFwaNohFxsuBpuCJR8g_e1vzs3vgs#association
https://w3id.org/biolink/vocab/association_type
https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation
http://purl.org/np/RA5I80bakV6K-AUQuFwaNohFxsuBpuCJR8g_e1vzs3vgs#association
https://w3id.org/biolink/vocab/provided_by
https://w3id.org/um/NeuroDKG
http://purl.org/np/RA5I80bakV6K-AUQuFwaNohFxsuBpuCJR8g_e1vzs3vgs#association
https://w3id.org/biolink/vocab/relation
https://schema.org/TreatmentIndication
https://identifiers.org/drugbank:DB06769
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Drug
http://purl.org/np/RA5I80bakV6K-AUQuFwaNohFxsuBpuCJR8g_e1vzs3vgs#provenance
http://purl.org/np/RA5I80bakV6K-AUQuFwaNohFxsuBpuCJR8g_e1vzs3vgs#assertion
http://www.w3.org/ns/prov#wasAttributedTo
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RA5I80bakV6K-AUQuFwaNohFxsuBpuCJR8g_e1vzs3vgs#pubinfo
http://purl.org/np/RA5I80bakV6K-AUQuFwaNohFxsuBpuCJR8g_e1vzs3vgs#sig
http://purl.org/nanopub/x/hasAlgorithm
RSA
http://purl.org/np/RA5I80bakV6K-AUQuFwaNohFxsuBpuCJR8g_e1vzs3vgs#sig
http://purl.org/nanopub/x/hasPublicKey
MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB
http://purl.org/np/RA5I80bakV6K-AUQuFwaNohFxsuBpuCJR8g_e1vzs3vgs#sig
http://purl.org/nanopub/x/hasSignature
GqyRk24dx5beTXKfGlW3ci8maICZ8+4mY5osqfCLIb+5MEmMrwpGvFLHSbhiNmgENgmI8mMWHO1YTwHmQu68KG4hX07WINWpInFxqiy8eYhT1yhGn0Sfdzl+ZidIubsvzNjVyTuA6Fh4aspkVlIqW88Tcwfqk6vfusERm6x9Kx0=
http://purl.org/np/RA5I80bakV6K-AUQuFwaNohFxsuBpuCJR8g_e1vzs3vgs#sig
http://purl.org/nanopub/x/hasSignatureTarget
http://purl.org/np/RA5I80bakV6K-AUQuFwaNohFxsuBpuCJR8g_e1vzs3vgs
http://purl.org/np/RA5I80bakV6K-AUQuFwaNohFxsuBpuCJR8g_e1vzs3vgs
http://purl.org/dc/terms/created
2021-06-30T09:01:14.488+02:00
http://purl.org/np/RA5I80bakV6K-AUQuFwaNohFxsuBpuCJR8g_e1vzs3vgs
http://purl.org/dc/terms/creator
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RA5I80bakV6K-AUQuFwaNohFxsuBpuCJR8g_e1vzs3vgs
https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate
http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM
http://purl.org/np/RA5I80bakV6K-AUQuFwaNohFxsuBpuCJR8g_e1vzs3vgs
https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate
http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM
http://purl.org/np/RA5I80bakV6K-AUQuFwaNohFxsuBpuCJR8g_e1vzs3vgs
https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate
http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs